Evaluation of tumor mutation burden (TMB) in tumor (tDNA) and plasma cell free DNA (cfDNA) in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with a combination of cetuximab and nivolumab (C+N).
Christine H. Chung(Moffitt Cancer Center), Aik Choon Tan(Colorado School of Public Health), Robbert J.C. Slebos(University of Iowa), James W. Rocco(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Laxmi Parida(IBM (United States)), Kedar Kirtane(Moffitt Cancer Center), Nabil F. Saba(Emory University), Brian P. Danysh(Broad Institute), Robin Park(Moffitt Cancer Center), Nicholas J. Haradhvala(Broad Institute), Ritu Chaudhary(Moffitt Cancer Center), Maria I. Poole(Moffitt Cancer Center), Conor Steuer(Emory University), Priyanka Bhateja(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jiannong Li(Moffitt Cancer Center), Xiaofei Song(Moffitt Cancer Center), Marcelo Bonomi, Graydon Moorhead(Broad Institute), Gad Getz(Broad Institute)
Cited by 1
Related Papers
Integrative genomics viewer
|Nature Biotechnology|2011|16.5k
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k